BRIEF-GSK receives EU marketing authorisation for COPD drug Anoro

Thu May 8, 2014 11:08am EDT

May 8 (Reuters) - GlaxoSmithKline Plc :

* GSK receives EU marketing authorisation for Anoro

* Anoro (Umeclidinium/Vilanterol) gains marketing authorisation in Europe for treatment of COPD

* Licensed strength in europe is umec/vi 55mcg / 22mcg

* Theravance is obligated to make a milestone payment to GSK of $15 million following marketing authorisation for umec/vi by European Commission

* First launch is expected to take place in europe in Q2-3 2014 with additional launches to follow thereafter

* Further $15 million payment to GSK will follow launch of umec/vi in Europe Source text for Eikon: Further company coverage:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.